Connect with us

Business

Police pursuit ends with crash in Brampton – CBC.ca

Published

 on


A police pursuit of an allegedly stolen vehicle in Brampton early Wednesday ended with the 33-year-old male driver being airlifted to hospital with life-threatening injuries.

Ontario’s police watchdog, the Special Investigations Unit (SIU), is now probing the incident.

Peel police initially received a call, shortly after midnight, from a citizen who reported that the driver of a white work van was speeding and driving erratically, according to Const. Danny Marttini.

Officers located the van on Rutherford Road and tried to stop the driver. During the ensuing pursuit, the vehicle crashed with a police cruiser, according to an SIU release issued later Wednesday morning. 

The driver didn’t stop, but instead made his way to Kennedy Road North and Williams Parkway, where the vehicle hit a second cruiser, mounted the grass median and struck a cement barrier.

Firefighters were called in to extract the man, who was taken to hospital in critical condition. 

Meanwhile, a police cruiser with a damaged front-end could be seen on Kennedy Road, north of Church Street.

Three investigators, three forensic investigators and one collision reconstructionist have been assigned to the case, the SIU said in its release. 

The SIU is called to investigate any incident involving an Ontario police officer and a member of the public that leads to death, serious injury or an allegation of sexual assault.

Anyone with information is asked to contact the lead investigator at 1-800-787-8529

Let’s block ads! (Why?)



Source link

Continue Reading

Business

What’s behind the EU-AstraZeneca vaccine row? – Al Jazeera English

Published

 on


The European Union and AstraZeneca are engaged in a bitter row over the United Kingdom-based pharmaceutical giant’s supply of coronavirus vaccines to the bloc.

The dispute began last week when AstraZeneca, a British-Swedish company, said it would cut supplies to the EU in the first quarter of this year, citing production issues.

Crisis talks between the pair on Wednesday failed to achieve a breakthrough, prompting fears the argument over how many doses the EU will receive could continue.

The EU contract with AstraZeneca is an advance purchase agreement for the supply of at least 300 million doses, delivered in stages, provided the vaccine is approved as safe and effective.

The dispute has raised concerns about the international competition for limited supplies of the shots, which are hoped to ease the COVID-19 pandemic.

What caused the EU and AstraZeneca row?

Last week, AstraZeneca, which partnered with the UK’s Oxford University to develop its vaccine, said it would cut supplies to the EU in the first quarter of this year, blaming production issues at European manufacturing plants.

An EU official said that meant the 27-member bloc would receive 60 percent fewer doses than initially agreed, down from 80 million to 31 million doses overall in the first three months of 2021.

The news came as a body blow to the EU, which has been slow in rolling out vaccines compared with some other regions and countries, especially the UK, a former member state.

The bloc has signed deals for six different vaccines, but so far its medicines regulators have only authorised the use of two – by Pfizer-BioNTech and Moderna.

The European Medicines Agency is expected to greenlight the AstraZeneca vaccine on Friday.

What has each side said?

Following Wednesday’s talks, EU Health Commissioner Stella Kyriakides said there was still a “continued lack of clarity” from AstraZeneca on the delivery schedule and called on the company to detail how it would supply the bloc with reserved vaccine doses.

“We will work with the company to find solutions and deliver vaccines rapidly for EU citizens,” she said in a post on Twitter.

A spokesman for AstraZeneca said after the meeting that the company was committed to “coordination”.

But Pascal Soriot, AstraZeneca’s chief executive, rejected the EU’s assertion that the company was failing to honour its delivery commitments.

Soriot said vaccine delivery figures set out in AstraZeneca’s contract with the EU were just targets.

“Our contract is not a contractual commitment, it’s a best effort,’’ Soriot told Italian newspaper La Repubblica on Tuesday. “Basically, we said we’re going to try our best, but we can’t guarantee we’re going to succeed.”

Soriot also told reporters that vaccines meant for the EU were produced in four plants in Belgium, the Netherlands, Germany and Italy.

But European Commission officials said on Wednesday that the bloc’s contract with AstraZeneca stipulated that the company had also committed to providing vaccines from two factories in the UK.

The EU’s contract with AstraZeneca is confidential and cannot be released without the agreement of both sides. The bloc has asked the company for permission to release the contract.

How will the argument be resolved?

As of yet, it is unclear how the dispute will be settled.

The EU’s Kyriakides said on Wednesday that AstraZeneca must “live up to its contractual, societal and moral obligations” and deliver the vaccine in the quantities, and by the deadlines, originally set out by their agreement.

Kyriakides added that the firm should divert stock from its UK facilities if it it is unable to meet commitments from factories in the EU.

But a senior UK government minister said on Thursday the country’s supply of vaccines from AstraZeneca must not be interrupted.

“It is the case that the supplies which have been planned, paid for and scheduled should continue,” the Conservative Party’s Michael Gove told the BBC. “Absolutely, there will be no interruption to that.”

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Ontario extends 2nd dose of Pfizer COVID-19 vaccine to 35 days due to delays – CityNews Toronto

Published

 on


The province’s top doctor has once again revised the timing of when people can get the second dose of the COVID-19 vaccine.

In a memo sent to hospital CEOs and Medical Officers of Health on Wednesday, Ontario’s Chief Medical Officer of Health Dr. David Williams has recommended extending the dosing interval for the second shot of the Pfizer-BioNtech vaccine to 35 days and no more than 42 days.

Previously, the province sent out guidance that the second shot be given anytime between 21 and 42 days after the first dose was administered.

The recommendation applies to everyone outside of long-term care settings, essential caregivers and staff, and First Nations elder care homes, where the second doses are set to be administered between 21 and 27 days later.

“We recognize that this allocation reduction will have significant impact on the current level of vaccine delivery across the province,” Williams said in the memo.

“The extended dosage interval is a direct response to the temporarily reduced vaccine availability from the federal government and uncertainty regarding the stability of supply in the near-term.”

Williams points out that there are no scheduled deliveries of the Pfizer-BioNtech vaccine this week and just over 26,000 doses expected the first week of February. The province says it has yet to receive information on how many doses are to be delivered for the weeks of Feb. 8 and 15th.

Pfizer has advised Canada, and other countries, that delivery of its COVID-19 vaccine would be impacted for several weeks due to work to expand its European manufacturing facility.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Calgary company begins clinical trials for Canadian-made COVID vaccine candidate – CP24 Toronto's Breaking News

Published

 on


The Canadian Press


Published Tuesday, January 26, 2021 5:47PM EST


Last Updated Tuesday, January 26, 2021 5:48PM EST

A prospective COVID-19 vaccine touted as a made-in-Canada response has begun human clinical trials in Toronto, and the company says it’s already preparing a followup that will target more infectious variants.

Providence Therapeutics of Calgary says if all goes well, it could start manufacturing millions of doses of its first prospective vaccine by the end of the year, guaranteeing a Canadian stockpile that wouldn’t be subject to global supply pressures or competition.

That’s if the formulation proves safe and effective, of course.

Among the challenges of developing a vaccine amid a raging pandemic is the uncertainty of how more infectious variants now emerging will complicate the COVID battle.

Even if successful, by the time Providence Therapeutics releases its vaccine hopeful, much of the country could be in the throes of a more infectious virus that does not respond to this formulation, said company CEO Brad Sorenson.

“We don’t believe that this is going to be resolved by a single vaccine,” said Sorenson, whose biotech also produces a personalized mRNA-based vaccine against cancer.

It’s a challenge now facing Pfizer-BioNTech and Moderna, which have each said its products appear to respond well to the variant initially identified in the United Kingdom, and to a lesser degree, the variant first detected in South Africa.

Moderna said earlier this week it plans to test two booster vaccines aimed at the variant associated with South Africa.

Sorenson said Providence is already internally testing a vaccine candidate that targets the variants, and he hoped to begin clinical trials by the end of the year.

“We believe that there’s going to be a need to be in a position of readiness to be able to respond as these variants are coming up, and to be able to make sure that we have that capacity.”

That doesn’t mean Providence is changing production runs just yet.

Sorenson said the immediate focus is to establish the safety and efficacy of its COVID-19 vaccine, dubbed PTX-COVID19-B and designed in the early days of the pandemic last March.

It uses messenger RNA technology and focuses on the spike protein located on the surface of a coronavirus that initiates infection, similar to the Pfizer-BioNTech and Moderna products.

The trial involves 60 healthy volunteers aged 18 to 25 who will be monitored for 13 months, with the first results expected in February.

The subjects are divided into four groups of 15, three of which will get three different doses. The fourth group gets a placebo.

Sorenson said immediate pandemic efforts should be focused on the novel coronavirus currently devastating many parts of the country.

“It’s a matter of capacity. Right now these variants are there, they’re concerning, and we’re keeping a close eye on it, but that’s not predominantly what the needs of the population are,” said Sorenson.

“Right now the needs of the population are still tied to the primary spike protein virus that’s out there and is ravaging around the world.”

Sorenson said his next vaccine candidate takes a broader approach by attempting to elicit a T-cell response, thereby creating a longer-term vaccine “and cover what we believe would be a lot more variants.”

“We have to prove it out, but we believe that if we are successful that it will allow for a much more durable immunity and a much broader immunity.”

The other goal is to prepare for large-scale manufacturing in Calgary, if all goes well with the trials and approval process.

Sorenson said doses for the Phase 1 trial are being made in Toronto, but the plan is to commercially manufacture the completed vaccine through a contract with the Calgary-based Northern RNA Inc.

That won’t be up and running by the end of the year, Sorenson allowed, so the short-term plan is to send raw materials made in Canada to a plant in the United States that would make the commercial product.

Eventually, the whole process would be completed in Canada, he said.

“We’re building the entire chain within Canada, so we’re not going to run into a problem where this particular input into the vaccine is unavailable,” he said.

Much of this also depends on financial support from the federal government, Sorenson added.

While the National Research Council of Canada has backed Phase 1 trials, Sorenson said he’s awaiting word on further support. He’d also like Ottawa to back Providence’s efforts to address the new COVID variants.

“They’ve already recognized the importance of mRNA technology. What they don’t realize is the power of mRNA technology to be responsive to these challenges that are coming up,” he said.

“Hopefully the politicians and the people that cut the cheques and write the policies that give direction to the bureaucrats will hear that and we’ll start seeing a more concerted approach that looks at a fuller picture.”

Pending regulatory approval, Sorenson said a larger, international Phase 2 trial may start in May with seniors, younger subjects and pregnant people, followed by an even broader Phase 3 trial.

The Providence project is just one of several Canadian efforts underway to develop a COVID-19 vaccine.

The biopharmaceutical company Medicago, based in Quebec City, began clinical trials on its plant-based candidate last July. If successful, the company has said manufacturing would take place in Durham, N.C., until it can complete a large-scale manufacturing facility set for Quebec City.

And last month, Health Canada gave the green light to the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan to launch its Phase 1 clinical vaccine trial.

Infectious disease expert Jason Kindrachuk, who works with VIDO but is not involved with its vaccine candidate, said a varied vaccine strategy will be key to controlling the pandemic.

“Vaccines are not necessarily a one-size-fits-all and maybe with this pandemic, people are getting a greater appreciation for some of the logistical hurdles of trying to transport vaccines. Cold chain storage is not something most people knew about or thought about prior to COVID and everybody in the community now I think has heard about it,” said Kindrachuk, a visiting scientist from the University of Manitoba and Canada Research Chair.

“This is something that, in regards to vaccine development, we really have to put a lot of thought into as a research community because of the fact that we have to make vaccines that are accessible for the communities that are ultimately going to be treated with them.”

Ontario Health Minister Christine Elliott acknowledged Tuesday that appetite was strong for a homegrown answer but noted Providence was still a considerable ways from offering a viable option.

“First it has to go through the appropriate approval process, go through Health Canada to make sure that it’s going to be satisfactory and safe and efficacious,” said Elliott.

Let’s block ads! (Why?)



Source link

Continue Reading

Trending